UY27882A1 - Compuestos quimicos - Google Patents

Compuestos quimicos

Info

Publication number
UY27882A1
UY27882A1 UY27882A UY27882A UY27882A1 UY 27882 A1 UY27882 A1 UY 27882A1 UY 27882 A UY27882 A UY 27882A UY 27882 A UY27882 A UY 27882A UY 27882 A1 UY27882 A1 UY 27882A1
Authority
UY
Uruguay
Prior art keywords
chemical compounds
solvates
salts
compounds
hyperlipidemia
Prior art date
Application number
UY27882A
Other languages
English (en)
Inventor
Starke
Lindqvist
Nordberg
Lemurell
Dahlstrom
Skjaret Tore
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY27882A1 publication Critical patent/UY27882A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen compuestos de fórmula (I) : (en donde los grupos variables son como se definieron en el presente documento) sales, solvatos, solvatos de dichas sales y profármacos farmacéuticamente aceptable de los mismos y su utilización como inhibidores de la absorción del colesterol para el tratamiento de la hiperlipidemia.Asimismo se describen procedimientos para la fabricación de los mismos y composiciones farmacéuticas que los contienen.
UY27882A 2002-07-05 2003-07-04 Compuestos quimicos UY27882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0215579.4A GB0215579D0 (en) 2002-07-05 2002-07-05 Chemical compounds

Publications (1)

Publication Number Publication Date
UY27882A1 true UY27882A1 (es) 2004-02-27

Family

ID=9939901

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27882A UY27882A1 (es) 2002-07-05 2003-07-04 Compuestos quimicos

Country Status (21)

Country Link
US (1) US7470678B2 (es)
EP (1) EP1521742A1 (es)
JP (1) JP2006501184A (es)
CN (2) CN100528842C (es)
AR (1) AR041185A1 (es)
BR (1) BR0312280A (es)
CA (1) CA2491789A1 (es)
GB (1) GB0215579D0 (es)
IL (1) IL165820A0 (es)
IS (1) IS7648A (es)
MX (1) MXPA04012936A (es)
NO (1) NO20050016L (es)
NZ (1) NZ537124A (es)
PL (1) PL374725A1 (es)
RU (2) RU2333199C2 (es)
SA (1) SA02230379B1 (es)
TW (1) TW200404058A (es)
UA (1) UA78564C2 (es)
UY (1) UY27882A1 (es)
WO (1) WO2004005247A1 (es)
ZA (1) ZA200410340B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
CA2550215A1 (en) * 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CA2550373C (en) * 2003-12-23 2012-01-31 Merck & Co., Inc. Anti-hypercholesterolemic compounds
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
AU2005311930B9 (en) 2004-12-03 2009-09-10 Merck Sharp & Dohme Corp. Substituted piperazines as CB1 antagonists
CN101243072A (zh) 2005-06-20 2008-08-13 先灵公司 用作组胺h3拮抗剂的哌啶衍生物
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR056866A1 (es) * 2005-06-22 2007-10-31 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
WO2007108007A1 (en) * 2006-03-23 2007-09-27 Unichem Laboratories Limited A process for the preparation of ezetimibe via a novel intermediate
JP4880348B2 (ja) * 2006-04-25 2012-02-22 壽製薬株式会社 アズレン誘導体及びそれを有効成分とする血清コレステロール低下剤
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20100069347A1 (en) * 2006-11-02 2010-03-18 Morriello Gregori J Heterocyclyl-substituted anti-hypercholesterolemic compounds
US20100125059A1 (en) * 2007-03-06 2010-05-20 Teijin Pharma Limited 1-biarylazetidinone derivative
DE102007063671A1 (de) * 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EP3243385B1 (en) 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
MX363161B (es) 2011-10-28 2019-03-13 Lumena Pharmaceuticals Inc Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica.
ES2633766T3 (es) 2011-10-28 2017-09-25 Lumena Pharmaceuticals Llc Inhibidores de reciclaje de ácido biliar para el tratamiento de enfermedades de hígado colestático pediátrico
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2958562A4 (en) 2013-02-22 2016-08-10 Merck Sharp & Dohme BICYCLIC ANTIDIABETIC COMPOUNDS
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
JP2016514684A (ja) 2013-03-15 2016-05-23 ルメナ ファーマシューティカルズ エルエルシー 原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015092448A1 (en) 2013-12-18 2015-06-25 Rudjer Boskovic Institute Beta-lactam cholesterol absorption inhibitors
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN109369491A (zh) * 2018-12-10 2019-02-22 无锡福祈制药有限公司 一类新的依替米贝衍生物及其制备方法
CN109384700A (zh) * 2018-12-10 2019-02-26 无锡福祈制药有限公司 一类新的依折麦布类似物及其制备方法
CN109293547A (zh) * 2018-12-10 2019-02-01 无锡福祈制药有限公司 一类新的依折麦布衍生物及其制备方法
AU2020221834A1 (en) 2019-02-12 2021-09-02 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0524595A1 (en) 1991-07-23 1993-01-27 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
KR0176001B1 (ko) 1993-07-09 1999-03-20 에릭 에스. 딕커 아제티디논의 합성방법
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
AU2943095A (en) 1994-06-20 1996-01-15 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
AU2453295A (en) 1994-09-20 1996-04-19 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
ES2175141T3 (es) 1995-10-31 2002-11-16 Schering Corp 2-azetidinonas sustituidas con azucares utiles como agentes hipocolesterolemicos.
AU7472896A (en) 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
CA2353981C (en) 1998-12-07 2005-04-26 Schering Corporation Process for the synthesis of azetidinones
NZ512532A (en) 1998-12-23 2003-12-19 G Combinations for treating cardiovascular diseases like hypercholesterolemia and atherosclerosis
CN1249250C (zh) 1999-04-05 2006-04-05 先灵公司 用于制备1－(4－氟苯基)－3(R)－[3(S)－羟基－3－(4－氟苯基)丙基]－4(S)－(4－羟苯基)－2－β丙内酰胺的立体选择性微生物还原反应
US6593078B1 (en) 1999-04-16 2003-07-15 Schering Corporation Use of azetidinone compounds
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
DK1347987T3 (da) 2000-12-20 2005-01-31 Schering Corp Sukkersubstituerede 2-azetidinoner, der er anvendelige som hypocholesterolæmiske midler
KR100833089B1 (ko) 2000-12-21 2008-05-29 사노피-아벤티스 도이칠란트 게엠베하 신규한 1,2-디페닐아제티딘온 및 당해 화합물을 함유하는 지질 대사 장애를 치료하기 위한 약제학적 조성물
CN1221546C (zh) 2000-12-21 2005-10-05 阿文蒂斯药物德国有限公司 二苯基氮杂环丁酮衍生物、它们的制备方法、含有这些化合物的药物和它们的用途
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
PL205343B1 (pl) 2001-01-26 2010-04-30 Schering Corp Zastosowanie inhibitora wchłaniania sterolu
EP1785144A3 (en) 2001-01-26 2007-05-23 Shering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CZ309209B6 (cs) 2001-01-26 2022-05-25 Schering Corporation Farmaceutický prostředek
EP1671650A1 (en) 2001-01-26 2006-06-21 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
EP1353694B1 (en) 2001-01-26 2007-12-19 Schering Corporation Combinations of ezetimibe with aspirine for treating vascular conditions
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
WO2002072104A2 (en) 2001-03-08 2002-09-19 Merck & Co., Inc. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
NZ527852A (en) 2001-03-28 2005-03-24 Schering Corp Enantioselective synthesis of azetidinone intermediate compounds
DK1392287T3 (da) 2001-05-25 2007-03-19 Schering Corp Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ES2312624T3 (es) 2001-09-21 2009-03-01 Schering Corporation Metodos para tratar o prevenir la inflamacion vascular usando un inhibidor (inhibidores) de la absorcion de esterol.
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
WO2003088962A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Combination therapy using a ppar alpha/gamma agonist
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US6941867B2 (en) 2002-07-01 2005-09-13 Special Devices, Inc. Initiator with a slip plane between an ignition charge and an output charge
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US6761509B2 (en) 2002-07-26 2004-07-13 Jan Erik Jansson Concrete module for retaining wall and improved retaining wall
CN1678296A (zh) 2002-07-30 2005-10-05 卡里凯昂公司 依泽替米贝的组合物和治疗胆固醇有关的良性与恶性肿瘤的方法
US6960047B2 (en) 2002-08-02 2005-11-01 Innovative Technology Application, Inc. Protection barrier apparatus
AU2003253341C1 (en) 2002-08-06 2009-09-24 Sanofi-Aventis Deutschland Gmbh Method for isolating an intestinal cholesterol binding protein
US20040092499A1 (en) 2002-11-06 2004-05-13 Schering Corporation Methods and therapeutic combinations for the treatment of autoimmune disorders
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CN1805926A (zh) 2003-05-05 2006-07-19 兰贝克赛实验室有限公司 二苯基氮杂环丁酮衍生物的反式异构体的制备方法
WO2004107958A2 (en) 2003-05-30 2004-12-16 Schering Corporation Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
US7002008B2 (en) 2003-06-16 2006-02-21 Bomi Patel Framroze Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1660456A2 (en) 2003-08-25 2006-05-31 Microbia Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
EP1660446A2 (en) * 2003-08-28 2006-05-31 Microbia, Inc. Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
EP1522541A1 (en) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
EP1682117A1 (en) 2003-10-30 2006-07-26 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents
WO2005042692A2 (en) 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
US20050096307A1 (en) 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
PL380414A1 (pl) 2003-11-10 2007-01-22 Microbia, Inc. 4-Diarylo-1- fenyloazetydyn-2-ony
WO2005049592A1 (en) 2003-11-24 2005-06-02 Hetero Drugs Limited A novel process for ezetimibe intermediate
EP1695706A1 (en) 2003-12-17 2006-08-30 Dainippon Sumitomo Pharma Co., Ltd. Medicinal compositions and combinations
CA2550215A1 (en) * 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
CA2550373C (en) 2003-12-23 2012-01-31 Merck & Co., Inc. Anti-hypercholesterolemic compounds
US20050171080A1 (en) 2003-12-23 2005-08-04 Dr. Reddy's Laboratories, Inc. Polymorphs of ezetimibe and process for preparation thereof
WO2005066120A2 (en) 2003-12-30 2005-07-21 Ranbaxy Laboratories Limited Process for asymmetric synthesis of hydroxy-alkyl substituted azetidinone derivatives
CA2553769C (en) 2004-01-16 2011-01-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
AP2006003832A0 (en) 2004-01-20 2006-12-31 Panacea Biotec Ltd Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof
AR049184A1 (es) 2004-05-21 2006-07-05 Aventis Pharma Gmbh Procedimiento para la preparacion de derivados de 1, 4 - difenilazetidinona en presencia de agentes de sililacion y de un catalizador de ciclacion
DE102004025072A1 (de) 2004-05-21 2005-12-15 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten
WO2006017257A2 (en) 2004-07-12 2006-02-16 Phenomix Corporation Azetidinone derivatives
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
JP2008514718A (ja) 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
US20060160785A1 (en) 2004-12-03 2006-07-20 Judith Aronhime Ezetimibe polymorphs
WO2006068990A1 (en) 2004-12-20 2006-06-29 Schering Corporation Process for the synthesis of azetidinones
IL166149A0 (en) 2005-01-05 2006-01-15 Hadasit Med Res Service Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity
WO2006086562A2 (en) 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
US20090186834A1 (en) 2005-03-24 2009-07-23 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
US20070049748A1 (en) 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
TW200806623A (en) 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
US7498431B2 (en) 2005-12-01 2009-03-03 Bomi Patel Framroze Process for the preparation of chiral azetidinones

Also Published As

Publication number Publication date
PL374725A1 (en) 2005-10-31
BR0312280A (pt) 2005-04-12
EP1521742A1 (en) 2005-04-13
CN100528842C (zh) 2009-08-19
US20050239766A1 (en) 2005-10-27
US7470678B2 (en) 2008-12-30
IS7648A (is) 2005-01-13
TW200404058A (en) 2004-03-16
NZ537124A (en) 2008-03-28
UA78564C2 (en) 2007-04-10
IL165820A0 (en) 2006-01-15
CN101058556A (zh) 2007-10-24
WO2004005247A1 (en) 2004-01-15
CN1665783A (zh) 2005-09-07
SA02230379B1 (ar) 2008-09-02
RU2004137279A (ru) 2005-09-10
JP2006501184A (ja) 2006-01-12
RU2008107146A (ru) 2009-09-10
AR041185A1 (es) 2005-05-04
RU2333199C2 (ru) 2008-09-10
AU2003242850A1 (en) 2004-01-23
NO20050016L (no) 2005-03-01
ZA200410340B (en) 2005-10-20
CA2491789A1 (en) 2004-01-15
MXPA04012936A (es) 2005-05-16
GB0215579D0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
UY27882A1 (es) Compuestos quimicos
UY28691A1 (es) Derivados de difenilazetidona
UY28695A1 (es) Derivados de difenilazetidona
UY29614A1 (es) Compuestos químicos
UY29613A1 (es) Compuestos quimicos vi
UY29607A1 (es) Compuestos quimicos
UY27846A1 (es) Compuestos quimicos
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
ECSP066302A (es) Omega-carboxiaril-difenil-urea sustituida con flúor para el tratamiento y la prevención de enfermedades y afecciones
ECSP078053A (es) Nuevos derivados de 2-azetidinona útiles en el tratamiento de condiciones de hiperlipidemia
UY27437A1 (es) Compuestos químicos
UY28572A1 (es) Compuestos novedosos
UY27436A1 (es) Compuestos químicos
UY28679A1 (es) Nuevos derivados organofosforados de los indazoles y utilización como médicamentos.
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
UY28510A1 (es) Compuestos quimicos
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
PA8589801A1 (es) Aminoalcoxiindoles